Prysmian

PHARMAS COME BACK (POSSIBLY)

12/06/25 -"Only a month ago we were lamenting the weakness of Pharmas, the second larget sector by market cap.  The tide may have turned, strangely as part of a risk-on phase in European equities: Pharmas ..."

PDF page sample
Pages
60
Language
English
Published on
12/06/25
Download
You may also be interested by these reports :
12/06/25
Since our last teaser, the stock has risen by 72.2%. While the share price remained largely flat for much of 2023, it experienced strong and steady ...
11/06/25
Agreed personnel cost reductions support strong EBITDA margin improvement – Target price raised to EUR 2.00
05/06/25
Burckhardt Compression reported strong FY24 results, though a change in revenue recognition affects comparability. Despite management’s efforts to ...
05/06/25
Confident outlook for FY25/26 triggered by good order backlog, strong China Print and cost savings – No surprise regarding final FY24/25 figures

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO